These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 39118591)

  • 1. Prediction Model for Immunotherapy Efficacy in Hepatocellular Carcinoma Based on Alternative Splicing Sequencing Data.
    Shi H; Liu Y; Liu Z; Ge X; Wu J; Tang H; Zhang Y; Lu S
    Technol Cancer Res Treat; 2024; 23():15330338241265962. PubMed ID: 39118591
    [No Abstract]   [Full Text] [Related]  

  • 2. Predictive value of a stemness-based classifier for prognosis and immunotherapy response of hepatocellular carcinoma based on bioinformatics and machine-learning strategies.
    Chen E; Zou Z; Wang R; Liu J; Peng Z; Gan Z; Lin Z; Liu J
    Front Immunol; 2024; 15():1244392. PubMed ID: 38694506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA Damage Repair Status Predicts Opposite Clinical Prognosis Immunotherapy and Non-Immunotherapy in Hepatocellular Carcinoma.
    Chen Y; Wang X; Deng X; Zhang Y; Liao R; Li Y; Yang H; Chen K
    Front Immunol; 2021; 12():676922. PubMed ID: 34335575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Influence of Immune Heterogeneity on the Effectiveness of Immune Checkpoint Inhibitors in Multifocal Hepatocellular Carcinomas.
    Huang M; He M; Guo Y; Li H; Shen S; Xie Y; Li X; Xiao H; Fang L; Li D; Peng B; Liang L; Yu J; Kuang M; Xu L; Peng S
    Clin Cancer Res; 2020 Sep; 26(18):4947-4957. PubMed ID: 32527942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metastasis and basement membrane-related signature enhances hepatocellular carcinoma prognosis and diagnosis by integrating single-cell RNA sequencing analysis and immune microenvironment assessment.
    Wei S; Tan J; Huang X; Zhuang K; Qiu W; Chen M; Ye X; Wu M
    J Transl Med; 2024 Jul; 22(1):711. PubMed ID: 39085893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction of a novel immune-related lncRNA signature and its potential to predict the immune status of patients with hepatocellular carcinoma.
    Deng M; Lin JB; Zhao RC; Li SH; Lin WP; Zou JW; Wei W; Guo RP
    BMC Cancer; 2021 Dec; 21(1):1347. PubMed ID: 34923955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the role of the immune microenvironment in hepatocellular carcinoma: Implications for immunotherapy and drug resistance.
    Fu Y; Guo X; Sun L; Cui T; Wu C; Wang J; Liu Y; Liu L
    Elife; 2024 Aug; 13():. PubMed ID: 39146202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of prognostic markers for hepatocellular carcinoma based on the epithelial-mesenchymal transition-related gene BIRC5.
    Xu R; Lin L; Zhang B; Wang J; Zhao F; Liu X; Li Y; Li Y
    BMC Cancer; 2021 Jun; 21(1):687. PubMed ID: 34112092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD74 facilitates immunotherapy response by shaping the tumor microenvironment of hepatocellular carcinoma.
    Cheng J; Li J; Jiang X; Ma X; Li B; Zhai H; Luo X; Zhou Y; Wu J; Zhang Z; Chen S; Wang Y
    Mol Med; 2024 Aug; 30(1):116. PubMed ID: 39118044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma.
    Park DJ; Sung PS; Lee GW; Cho S; Kim SM; Kang BY; Hur W; Yang H; Lee SK; Lee SH; Jung ES; Seo CH; Ahn J; Choi HJ; You YK; Jang JW; Bae SH; Choi JY; Yoon SK
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single cell analyses reveal the PD-1 blockade response-related immune features in hepatocellular carcinoma.
    Li Y; Li F; Xu L; Shi X; Xue H; Liu J; Bai S; Wu Y; Yang Z; Xue F; Xia Y; Dong H; Shen F; Wang K
    Theranostics; 2024; 14(9):3526-3547. PubMed ID: 38948071
    [No Abstract]   [Full Text] [Related]  

  • 13. Identification of PANoptosis-related subtypes, construction of a prognosis signature, and tumor microenvironment landscape of hepatocellular carcinoma using bioinformatic analysis and experimental verification.
    Ouyang G; Li Q; Wei Y; Dai W; Deng H; Liu Y; Li J; Li M; Luo S; Li S; Liang Y; Pan G; Yang J; Gan T
    Front Immunol; 2024; 15():1323199. PubMed ID: 38742112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and validation of immune-related gene signature models for predicting prognosis and immunotherapy response in hepatocellular carcinoma.
    Liu Z; Yang L; Liu C; Wang Z; Xu W; Lu J; Wang C; Xu X
    Front Immunol; 2024; 15():1371829. PubMed ID: 38933262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
    Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
    World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of prognostic alternative splicing events related to the immune microenvironment of hepatocellular carcinoma.
    Yu S; Cai L; Liu C; Gu R; Cai L; Zhuo L
    Mol Med; 2021 Apr; 27(1):36. PubMed ID: 33832428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anlotinib potentiates anti-PD1 immunotherapy via transferrin receptor-dependent CD8
    Song F; Hu B; Liang XL; Cheng JW; Wang CG; Wang PX; Wang TL; Tang PJ; Sun HX; Guo W; Zhou J; Fan J; Chen Z; Yang XR
    Clin Transl Med; 2024 Aug; 14(8):e1738. PubMed ID: 39095323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitotic catastrophe heterogeneity: implications for prognosis and immunotherapy in hepatocellular carcinoma.
    Mao Z; Gao Z; Long R; Guo H; Chen L; Huan S; Yin G
    Front Immunol; 2024; 15():1409448. PubMed ID: 39015573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review.
    Li B; Yan C; Zhu J; Chen X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Jiang W; Fang W
    Front Immunol; 2020; 11():1037. PubMed ID: 32547550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integration of Clinical Trial Spatial Multiomics Analysis and Virtual Clinical Trials Enables Immunotherapy Response Prediction and Biomarker Discovery.
    Zhang S; Deshpande A; Verma BK; Wang H; Mi H; Yuan L; Ho WJ; Jaffee EM; Zhu Q; Anders RA; Yarchoan M; Kagohara LT; Fertig EJ; Popel AS
    Cancer Res; 2024 Aug; 84(16):2734-2748. PubMed ID: 38861365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.